Abstract:
PROBLEM TO BE SOLVED: To provide a compound having a specific structure, selectively inhibiting FTase with respect to GGTase and useful for the treatment of diseases relating to the intracellular signal transduction through Ras protein, etc., and the investigation of pathology relating to angiogenetic amplification. SOLUTION: The objective compound is expressed by formula (I) [X is a bond, an alkylene, S(O)n or the like; Y is an aryl, a heteroaryl or the like; R1 to R4 are each independently H, an aryl or the like or together form a bond, a condensed benzene ring or the like; T is CH(R5 ) (R5 is H or the like) or the like; V is H, a substituted aryl or the like; A2 is [C(R6 ) (R'6 )] (R6 and R'6 are each H or the like; and (p) is 0-4); and R7 and R8 are each H or the like]. The invention further relates to its isomer, diastereomer, pharmacologically permissible acid or base and its addition salt.
Abstract:
A compound having formula (I), wherein X denotes an alkylene group or chain, CO, S(O)n, -S(O)n-A1-, -CO-A1-, -A1-S(O)n-A'1, or A1-CO-A'1-; Y denotes a substituted or non-substituted aryl, heteroaryl, cycloalkyl or heterocyclalkyl group; W denotes a CO or CH2 group; T denotes a N(R1)- or N(R1)CO- group; V denotes a hydrogen atom or a substituted or non-substituted aryl or heteroaryl group; A2 denotes a [C(R2)(R'2)]p group; R1 and R2 are as defined in the description. Medicaments.
Abstract:
L'invention concerne de nouveaux composés répondant à la formule formule (I ): dans laquelle X représente une liaison ou un groupement alkylène, CO, S(O)n, *- S(O)n-A1-, *-CO-A1-, -A1-S(O)n-A'1- et -A1-CO-A'1- dans lesquels A1 et A'1, identiques ou différents, représentent un groupement alkylène et n vaut 0, 1 ou 2, le symbole "*" représentant le point de rattachement du groupement au cycloheptène; Y représente un groupement aryle, hétéroaryle, cycloalkyle ou hétérocycloalkyle; R1, R2, R3 et R4 représentent indépendamment l'un de l'autre un atome d'hydrogène ou un groupement aryle, hétéroaryle, cycloalkyle ou hétérocycloalkyle, ou bien R1, R2, R3 et R4, pris deux à deux , forment ensemble une liaison, ou bien R1 et R2, ou R2 et R3 ou R3 et R4, pris deux à deux avec les atomes de carbone auxquels ils sont liés, forment un cycle benzénique fusion né ou un hétérocycle fusionné aromatique ou partiellement hydrogéné; T représente un groupement -CH(R5)-, -N(R5)- ou *-N(R5)CO- dans lesquels R5 représente un atome d'hydrogène ou un groupement alkyle, aryle, hétéroaryle, arylalkyle ou hétéroarylalkyle, le symbole "*" représentant le point de rattachement du groupement au cycloheptène; V représente un atome d'hydrogène ou un groupement aryle ou hétéroaryle; A2 représente un groupement [C(R6)(R'6)]p où p vaut 0, 1, 2, 3 ou 4 lorsque T représente un groupement - CH(R5)- ou *-N(R5)CO- où p vaut 1, 2, 3 ou 4 lorsque T représente un groupement -N(R5)- , et R6 et R'6, identiques ou différents, représentent un atome d'hydrogène ou un groupement alkyle, alkényle, alkynyle, aryle, hétéroaryle, hétérocycloalkyle, arylalkyle éventuellement substitué, hétéroarylalkyle, hétérocycloalkylalkyle, R9 ou alkyle substitué par un groupement R9 où R9 représente un groupement -OR5,-N(R5)(R'5), -S(O)m R5, -CON(R5)(R'5), -N(R5)COR'5, -N(R5)SO2R'5, -SO2N(R5)(R'5), -N(R5)COO(R'5), m étant égal à 0, 1 ou 2, et R'5 prenant toutes les valeurs de R5. L'invention vise également les énantiomères et diastéréoisomères des composés de formule (I), ainsi que leu rs sels -52- d'addition à un acide ou à une base pharmaceutiquement acceptable. Les composés selon l'invention sont utiles à titre de médicaments pour le traitement des maladi es cancéreuses ainsi que pour le traitement de la resténose après angioplastie ou chirurgie vasculaire, et de la neurofibromatose de type I.
Abstract:
Dihydro- and tetrahydro-quinoline derivatives (I) are new. Dihydro- and tetrahydro-quinoline derivatives of formula (I) and their acid or base addition salts are new. R1 = H or a group of formula (i); A = H or -B'NZ1Z2; B' = 1-6C alkylene; Z1, Z2 = H, alkyl, 3-8C cycloalkyl or optionally substituted aryl; or NZ1Z2 = heterocycloalkyl or heteroaryl (optionally substituted); R2, R3 = alkyl, 3-8C cycloalkyl, heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl or aminoalkyl (optionally substituted on N with 1 or 2 alkyl, cycloalkyl, aryl or arylalkyl); or R2 + R3 = form with C of quinoline, 3-8C cycloalkyl or heterocycloalkyl (optionally substituted with alkyl, cycloalkyl, cycloalkylalkyl, aryl or arylalkyl); R40 = alkyl, 2-6C alkenyl, 2-6C alkynyl (all optionally substituted), H, Q or -V'-Q; V' = 1-6C alkylene, 2-6C alkenylene or 2-6C alkynylene; Q = 3-8C cycloalkyl, aryl, heterocycloalkyl, heteroaryl (all optionally substituted); R5, R41 = H; or R5 + R41 = bond; R6-R9 = H, halo, alkyl, 3-8C cycloalkyl or -OW'; W' = aryl, heteroaryl, arylalkyl, heteroarylalkyl (all optionally substituted), H, alkyl, acyl, 3-8C cycloalkyl or heterocycloalkyl; alkyl = 1-6C; aryl = phenyl, naphthyl or biphenyl; heterocycloalkyl = partially unsaturated 4- to 11-membered mono- or bi-cyclic ring containing 1-6 N, S or O; heteroaryl = aromatic or partially aromatic 4- to 11-membered mono- or bi-cyclic ring containing 1-6 N, S or O; substituted aryl, arylalkyl = aryl or arylalkyl substituted with at least one halo, alkyl, 1-6C alkoxy, 1-6C perhaloalkyl, amino (optionally substituted by 1 or 2 alkyl), CN, carboxy, 1-6C alkoxycarbonyl, aminocarbonyl (optionally substituted with 1 or 2 alkyl on N), nitro or OH; substituted alkyl, alkenyl, alkynyl and cycloalkyl = alkyl, alkenyl, alkynyl and cycloalkyl substituted with at least one OH, 1-6C alkoxy, 1-6C alkylthio, amino (optionally substituted with 1 or 2 alkyl), carboxy, nitro, CN, 1-6C alkoxycarbonyl or aminocarbonyl (optionally substituted with 1 or 2 alkyl on N); substituted heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, heteroarylalkyl = heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, heteroarylalkyl substituted with at least one halo, alkyl, 1-6C alkoxy, 1-6C perhaloalkyl, amino (optionally substituted with 1 or 2 alkyl), CN, carboxy, 1-6C alkoxycarbonyl, aminocarbonyl (optionally substituted with 1 or 2 alkyl on N), nitro, OH or oxo; and provided that R6-R9 are not all H and at least one of R6-R9 is -OW', that R2 and R3 are alkyl when R6-R9 are H, alkyl, alkoxy, R41 and R5 form a bond, R40 is other than H or alkyl; when (I) has one OH and R40 is other than H; when (I) has one methoxy and R40 is other than hydroxyalkyl; and (I) is other than 7-methoxy-2,2-diphenyl-1,2-dihydroquinoline. An Independent claim is also included for the preparation of (I).
Abstract:
Dihydro- and tetrahydro-quinoline derivatives (I) are new. Dihydro- and tetrahydro-quinoline derivatives of formula (I) and their acid or base addition salts are new. R1 = H or a group of formula (i); A = H or -B'NZ1Z2; B' = 1-6C alkylene; Z1, Z2 = H, alkyl, 3-8C cycloalkyl or optionally substituted aryl; or NZ1Z2 = heterocycloalkyl or heteroaryl (optionally substituted); R2, R3 = alkyl, 3-8C cycloalkyl, heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl or aminoalkyl (optionally substituted on N with 1 or 2 alkyl, cycloalkyl, aryl or arylalkyl); or R2 + R3 = form with C of quinoline, 3-8C cycloalkyl or heterocycloalkyl (optionally substituted with alkyl, cycloalkyl, cycloalkylalkyl, aryl or arylalkyl); R40 = alkyl, 2-6C alkenyl, 2-6C alkynyl (all optionally substituted), H, Q or -V'-Q; V' = 1-6C alkylene, 2-6C alkenylene or 2-6C alkynylene; Q = 3-8C cycloalkyl, aryl, heterocycloalkyl, heteroaryl (all optionally substituted); R5, R41 = H; or R5 + R41 = bond; R6-R9 = H, halo, alkyl, 3-8C cycloalkyl or -OW'; W' = aryl, heteroaryl, arylalkyl, heteroarylalkyl (all optionally substituted), H, alkyl, acyl, 3-8C cycloalkyl or heterocycloalkyl; alkyl = 1-6C; aryl = phenyl, naphthyl or biphenyl; heterocycloalkyl = partially unsaturated 4- to 11-membered mono- or bi-cyclic ring containing 1-6 N, S or O; heteroaryl = aromatic or partially aromatic 4- to 11-membered mono- or bi-cyclic ring containing 1-6 N, S or O; substituted aryl, arylalkyl = aryl or arylalkyl substituted with at least one halo, alkyl, 1-6C alkoxy, 1-6C perhaloalkyl, amino (optionally substituted by 1 or 2 alkyl), CN, carboxy, 1-6C alkoxycarbonyl, aminocarbonyl (optionally substituted with 1 or 2 alkyl on N), nitro or OH; substituted alkyl, alkenyl, alkynyl and cycloalkyl = alkyl, alkenyl, alkynyl and cycloalkyl substituted with at least one OH, 1-6C alkoxy, 1-6C alkylthio, amino (optionally substituted with 1 or 2 alkyl), carboxy, nitro, CN, 1-6C alkoxycarbonyl or aminocarbonyl (optionally substituted with 1 or 2 alkyl on N); substituted heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, heteroarylalkyl = heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, heteroarylalkyl substituted with at least one halo, alkyl, 1-6C alkoxy, 1-6C perhaloalkyl, amino (optionally substituted with 1 or 2 alkyl), CN, carboxy, 1-6C alkoxycarbonyl, aminocarbonyl (optionally substituted with 1 or 2 alkyl on N), nitro, OH or oxo; and provided that R6-R9 are not all H and at least one of R6-R9 is -OW', that R2 and R3 are alkyl when R6-R9 are H, alkyl, alkoxy, R41 and R5 form a bond, R40 is other than H or alkyl; when (I) has one OH and R40 is other than H; when (I) has one methoxy and R40 is other than hydroxyalkyl; and (I) is other than 7-methoxy-2,2-diphenyl-1,2-dihydroquinoline. An Independent claim is also included for the preparation of (I).
Abstract:
Dihydro- and tetrahydro-quinoline derivatives (I) are new. Dihydro- and tetrahydro-quinoline derivatives of formula (I) and their acid or base addition salts are new. R1 = H or a group of formula (i); A = H or -B'NZ1Z2; B' = 1-6C alkylene; Z1, Z2 = H, alkyl, 3-8C cycloalkyl or optionally substituted aryl; or NZ1Z2 = heterocycloalkyl or heteroaryl (optionally substituted); R2, R3 = alkyl, 3-8C cycloalkyl, heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl or aminoalkyl (optionally substituted on N with 1 or 2 alkyl, cycloalkyl, aryl or arylalkyl); or R2 + R3 = form with C of quinoline, 3-8C cycloalkyl or heterocycloalkyl (optionally substituted with alkyl, cycloalkyl, cycloalkylalkyl, aryl or arylalkyl); R40 = alkyl, 2-6C alkenyl, 2-6C alkynyl (all optionally substituted), H, Q or -V'-Q; V' = 1-6C alkylene, 2-6C alkenylene or 2-6C alkynylene; Q = 3-8C cycloalkyl, aryl, heterocycloalkyl, heteroaryl (all optionally substituted); R5, R41 = H; or R5 + R41 = bond; R6-R9 = H, halo, alkyl, 3-8C cycloalkyl or -OW'; W' = aryl, heteroaryl, arylalkyl, heteroarylalkyl (all optionally substituted), H, alkyl, acyl, 3-8C cycloalkyl or heterocycloalkyl; alkyl = 1-6C; aryl = phenyl, naphthyl or biphenyl; heterocycloalkyl = partially unsaturated 4- to 11-membered mono- or bi-cyclic ring containing 1-6 N, S or O; heteroaryl = aromatic or partially aromatic 4- to 11-membered mono- or bi-cyclic ring containing 1-6 N, S or O; substituted aryl, arylalkyl = aryl or arylalkyl substituted with at least one halo, alkyl, 1-6C alkoxy, 1-6C perhaloalkyl, amino (optionally substituted by 1 or 2 alkyl), CN, carboxy, 1-6C alkoxycarbonyl, aminocarbonyl (optionally substituted with 1 or 2 alkyl on N), nitro or OH; substituted alkyl, alkenyl, alkynyl and cycloalkyl = alkyl, alkenyl, alkynyl and cycloalkyl substituted with at least one OH, 1-6C alkoxy, 1-6C alkylthio, amino (optionally substituted with 1 or 2 alkyl), carboxy, nitro, CN, 1-6C alkoxycarbonyl or aminocarbonyl (optionally substituted with 1 or 2 alkyl on N); substituted heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, heteroarylalkyl = heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, heteroarylalkyl substituted with at least one halo, alkyl, 1-6C alkoxy, 1-6C perhaloalkyl, amino (optionally substituted with 1 or 2 alkyl), CN, carboxy, 1-6C alkoxycarbonyl, aminocarbonyl (optionally substituted with 1 or 2 alkyl on N), nitro, OH or oxo; and provided that R6-R9 are not all H and at least one of R6-R9 is -OW', that R2 and R3 are alkyl when R6-R9 are H, alkyl, alkoxy, R41 and R5 form a bond, R40 is other than H or alkyl; when (I) has one OH and R40 is other than H; when (I) has one methoxy and R40 is other than hydroxyalkyl; and (I) is other than 7-methoxy-2,2-diphenyl-1,2-dihydroquinoline. An Independent claim is also included for the preparation of (I).
Abstract:
Compound of formula (I):wherein:X represents a bond or alkylene, CO, S(O)n, -S(O)n-A1-, -CO-A1-, -A-S(O)n-A'1- or -A1-CO-A'1-,Y represents aryl, heteroaryl, cycloalkyl or heterocycloalkyl, each unsubstituted or substituted,R1, R2, R3 and R4 each independently of the others represent hydrogen or aryl, heteroaryl, cycloalkyl or heterocycloalkyl, each unsubstituted or substituted,or R1, R2, R3 and R4, taken in pairs, together form a bond, or form a fused benzene ring or a fused aromatic or partially unsaturated heterocycle,T represents -CH(R5)-, -N(R5)- or -N(R5)CO-,V represents hydrogen or unsubstituted or substituted aryl or heteroaryl,A2 represents [C(R6)(R'6)]p,R7 and R8 are as defined in the description,their isomers and addition salts thereof with a pharmaceutically acceptable acid or base and medicinal products containing the same are useful as farnesyl transferase inhibitors.
Abstract:
N, 3-Disubstituted azepane or azepan-2-one derivatives (I) are new. Azepane derivatives of formula (I) and their enantiomers, diastereomers and acid or base addition salts are new. W = CO or CH2; X = alkylene, CO, S(O)n, S(O)n-A1, CO-A1, A1-S(O)n-A1 or A1-CO-A1 (bonded to the ring at the left-hand terminal); or X may also be a direct bond if W = CH2; A1 = alkylene; n = 0-2; Y = aryl, heteroaryl, cycloalkyl or heterocycloalkyl (all optionally substituted (os) by R8); R1 - R4 = H or as for Y; or pairs of adjacent groups R1 - R4 may together form bonds; T = CHR5, NR5 or NR5CO (bonded to the ring at the left-hand terminal); R5 = H; or alkyl, aryl, heteroaryl, aralkyl or heteroaralkyl (all os by one or more R7); V = H; or aryl or heteroaryl (both os by one or more R7); A2 = -(CR6R'6)p; p = 0-4 (but not 0 if T = NR5); R6, R'6 = H, alkyl (os by R9), alkenyl, alkynyl or R9; R9 = OR5, NR5R'5, S(O)nR5, CONR5R'5, NR5COR'5, NR5SO2R'5, SO2NR5R'5 or NR5COOR'5; R'5 = as R5; R7 = halo, alkyl, alkoxy, OH, SH, alkylthio, CN, NH2 (os by 1 or 2 alkyl), NO2, COOH, alkoxycarbonyl, CONH2 (os by 1 or 2 alkyl), carbamoyl, os aryl, os aralkyl, os heteroaryl, os heteroaralkyl, os cycloalkyl, os cycloalkylalkyl, os heterocycloalkyl or os heterocycloalkylalkyl; R8 = halo, =O, OH, CN, NO2, COOH, alkoxycarbonyl, U-R80 or A80-U-R80; A80 = alkylene;and U = direct bond, O, NH, S(O)n, NHCO, CONH, SO2NH or NHSO2; R80 = alkyl, aryl, aralkyl, heteroaryl or heteroarylalkyl; alkyl or alkylene moieties have 1-6C; cycloalkyl moieties have 3-8C; heterocycloalkyl moieties are 5-7 membered and contain 1-3 of N, O and S as heteroatom(s); aryl moieties are phenyl or naphthyl; heteroaryl moieties are mono- or bicyclic 5-11 membered systems containing at least one aromatic ring and 1-5 of N, O and S as heteroatom(s); the substituents in os aryl, heteroaryl, aralkyl or heteroaralkyl are one or more of CN, alkylcarbonyl, CONH2 (os by 1 or 2 alkyl) or halo (in the ring part); and the substituents in os cycloalkyl, heterocycloalkyl, cycloalkylalkyl or heterocycloalkylalkyl are one or more of =O, CN, alkylcarbonyl, CONH2 (os by 1 or 2 alkyl) or halo (in the ring part). An Independent claim is included for the preparation of (I).
Abstract:
1,3-Disubstituted cycloheptene derivatives (I) are new. Cycloheptene derivatives of formula (I) and their enantiomers, diastereomers and acid or base addition salts are new. X = direct bond, alkylene, CO, S(O)n, S(O)n-A1, CO-A1, A1-S(O)n-A1 or A1-CO-A1 (bonded to the ring at the left-hand terminal); A1 = alkylene; n = 0-2; Y = aryl, heteroaryl, cycloalkyl or heterocycloalkyl (all optionally substituted (os) by R8); R1 - R4 = H or as for Y; or pairs of adjacent groups R1 - R4 may together form bonds; or R1 + R2, R2 + R3 or R3 + R4 = group completing a fused benzene ring or fused 5- or 6-membered aromatic or partially aromatic heterocycle containing 1 or 2 of N, O and S as heteroatom(s); T = CHR5, NR5 or NR5CO (bonded to the ring at the left-hand terminal); R5 = H; or alkyl, aryl, heteroaryl, aralkyl or heteroaralkyl (all os by one or more R7); V = H; or aryl or heteroaryl (both os by one or more R7); A2 = -(CR6R'6)p; p = 0-4 (but not 0 if T = NR5); R6, R'6 = H, alkyl (os by R9), alkenyl, alkynyl or R9; R9 = OR5, NR5R'5, S(O)nR5, CONR5R'5, NR5COR'5, NR5SO2R'5, SO2NR5R'5 or NR5COOR'5; R'5 = as R5; R7 = halo, alkyl, alkoxy, OH, SH, alkylthio, CN, NH2 (os by 1 or 2 alkyl), NO2, COOH, alkoxycarbonyl, CONH2 (os by 1 or 2 alkyl), carbamoyl, os aryl, os aralkyl, os heteroaryl, os heteroaralkyl, os cycloalkyl, os cycloalkylalkyl, os heterocycloalkyl or os heterocycloalkylalkyl; R8 = halo, =O, OH, CN, NO2, COOH, alkoxycarbonyl, U-R80 or A80-U-R80; A80 = alkylene; U = direct bond, O, NH, S(O)n, NHCO, CONH, SO2NH or NHSO2; R80 = alkyl, aryl, aralkyl, heteroaryl or heteroarylalkyl; alkyl or alkylene moieties have 1-6C; cycloalkyl moieties have 3-8C; heterocycloalkyl moieties are 5-7 membered and contain 1-3 of N, O and S as heteroatom(s); aryl moieties are phenyl or naphthyl; heteroaryl moieties are mono- or bicyclic 5-11 membered systems containing at least one aromatic ring and 1-5 of N, O and S as heteroatom(s); the substituents in os aryl, heteroaryl, aralkyl or heteroaralkyl are one or more of CN, alkylcarbonyl, CONH2 (os by 1 or 2 alkyl) or halo (in the ring part); the substituents in os cycloalkyl, heterocycloalkyl, cycloalkylalkyl or heterocycloalkylalkyl are one or more of =O, CN, alkylcarbonyl, CONH2 (os by 1 or 2 alkyl) or halo (in the ring part). An Independent claim is included for the preparation of (I).